Clario, GI Reviewers and RSIP Vision Team Up to Present a New AI Solution to Advance Clinical Trials for Inflammatory Bowel Diseases
Innovative, human-level AI technology will improve efficiency and consistency of Inflammatory Bowel Disease (IBD) scoring, advancing clinical trials of novel treatments for these debilitating ailments.
PHILADELPHIA, PA, Copenhagen, Denmark; San Mateo, CA; Boston, MA; & Jerusalem, Israel – March 6, 2023 – Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry and GI Reviewers, LLC Gastroenterology consultants and central readers, together with RSIP Vision, an experienced developer of groundbreaking AI technologies for medical imaging, today announced their new AI-based scoring system for inflammatory bowel diseases. The solution is expected to improve the reproducibility of colonoscopy video scoring, optimize workflow by shortening the time required for a human expert reader to score, and ultimately improve recruitment and reduce costs associated with clinical trials. Peer-reviewed results demonstrating the human-level performance of this innovative system were presented to the pharmaceutical and clinical trials industry community at the prestigious European Crohn’s and Colitis (ECCO) conference this week.
Inflammatory bowel diseases (IBD) such as Ulcerative Colitis (UC) and Crohn’s disease are mostly diagnosed by performing a colonoscopy. The level of disease is assessed by visual findings such as ulcers, erosions, and erythema, which are graded using visual scoring approaches. However, IBD scoring is a complex and time-consuming task, and reader assessments are often subjective, based on their training, experience and individual interpretation of the colonoscopy. The new AI-based system, developed at RSIP Vision under the scientific leadership of Clario and the clinical guidance from GI Reviewers, automatically computes the Mayo Endoscopic Score (MES) from colonoscopy videos in Ulcerative Colitis patients. The system was trained on hundreds of videos from multiple sites and devices, containing >100,000 images, and all scored under expert gastroenterologist supervision. Algorithm performance, as assessed by the Kappa metric, was found to be comparable to the performance of human reviewers. Building on the successes in UC, the system is being extended to support Crohn’s Disease scoring. This technology will allow generation of rich and detailed data from IBD videos, and increase the automation of clinical trial enrollment procedures.
“Central reading has become common in gastroenterology clinical trials due to the need for an unbiased, independent review of images ensuring the most reliable outcome data for assessing treatment efficacy,” said Dr. Marcela Vieira, Medical Director of Gastroenterology at Clario. “Our new AI-based solution will reduce known limitations of central reading, such as fatigue and inter-reader variability, and improve the reproducibility and speed of the readings. Using AI to support our reviewers is improving our capabilities across a range of clinical trial use cases, and will continue to be a game changer for medical research.”
Endoscopic videos such as colonoscopies present steep challenges for AI-based processing. Implementing this successful solution requires merging state-of-the-art neural network architectures with strong, robust, and ongoing validation processes, integrating the work of the clinical team as an integral part of the algorithm development.
“In addition to the Mayo score, our team trained the AI algorithm to detect which parts of the video lack medical interest and indicate this to the user, saving time and increasing efficiency,” said Moshe Safran, U.S. CEO at RSIP Vision. “The accuracy of the algorithm has been dramatically improved over the past year, and the performance of the AI has reached a level similar to that of a human expert,” Safran said.
“Colonoscopy scoring is a complex task, requiring years of training and experience to have the confidence, especially in more complex cases,” said Dr. Daniel Mishkin, CEO & Medical Director at GI Reviewers. “It has been a fascinating journey to see how this knowledge can be embedded in an automated algorithm that will help bring benefit to the patients of the future,” Mishkin said.
Clario, GI Reviewers, and RSIP Vision continue to collaborate to bring the benefits of AI to all aspects of IBD clinical trials. Upcoming plans include the expansion of the study to additional sites, AI-enabled extraction of rich and detailed video-based data to support deeper analytics by Pharma companies, expansion to Crohn’s disease scoring, AI-based automation of clinical trial enrollment, and ultimately the potential development of novel, quantitative, AI-enabled IBD scoring systems.
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over five million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years. For more information, go to Clario.com or follow us on LinkedIn and Twitter
About GI Reviewers, LLC
GI Reviewers, LLC offers consultations, reviews, and assessments in gastroenterology and all aspects of Medicine. Established in 2012, the service optimizes the expertise of various leaders in the field by centralizing the reviewing process and has developed software to facilitate and improve them. GI Reviewers’ expertise provides unbiased reviews with subspecialty evaluations in more than 150 gastroenterology studies, primarily in Inflammatory Bowel Disease, and more than 200 radiology, oncology, and ENT protocols. They prioritize timely delivery, state-of-the-art assessments, and excellent customer service.
About RSIP Vision
RSIP Vision is driving innovation in Visual Intelligence for Medical Devices, through advanced AI and computer vision applications. A proven global leader, with an extensive track record and over 25 years in the field, trusted by the largest, industry leading medical device companies. RSIP Vision offers clinical-grade AI solutions that provide medical device companies with advanced visual intelligence capabilities, to stay ahead of the rapid AI adoption curve and maintain their competitive edge. Our software can be found in medical devices in leading facilities worldwide, ensuring our customers remain at the forefront of the latest medical computer vision advances. RSIP Vision is headquartered in Jerusalem, Israel. More information is available on the company website: rsipvision.com